Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -222.91x is 39% below its 2-year average of -160.35x, around the middle of its 2-year range (-392.17x–-12.14x).
As of the fiscal period ended Thursday, June 30, 2022. 168.32% below its 12-month average of -83.07x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2022 (2022-06-30): -222.91x.
INTEREST COVERAGE RATIO
-222.91x
INTEREST COVERAGE RATIO AVG TTM
-83.07x
INTEREST COVERAGE RATIO AVG 3Y
-160.35x
INTEREST COVERAGE RATIO AVG 5Y
-160.35x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-168.32%
CURRENT VS 3Y AVG
-39.01%
CURRENT VS 5Y AVG
-39.01%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.44x
median of 527 covered companies
CURRENT VS SECTOR MEDIAN
-3361.27%
vs the sector median at left
Spero Therapeutics, Inc.
Market Cap
$68.90M
Interest Coverage Ratio
-222.91x
TTM Avg
-83.07x
3Y Avg
-160.35x
5Y Avg
-160.35x
Market Cap
$69.61M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$68.10M
Interest Coverage Ratio
-8.06x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$70.63M
Interest Coverage Ratio
-1174.00x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$71.23M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$65.87M
Interest Coverage Ratio
-14.86x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$65.86M
Interest Coverage Ratio
-21.57x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$65.85M
Interest Coverage Ratio
-632.78x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $68.90M | -222.91x | -83.07x | -160.35x | -160.35x |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | -8.06x | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | -663.04x | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | -1174.00x | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.87M | -14.86x | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.86M | -21.57x | N/A | N/A | N/A |
| XBiotech Inc. (XBIT)vs › | $65.85M | -632.78x | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | -1.54x | N/A | N/A | N/A |
Interest Coverage
-222.9x
Debt/Equity
0.05
Current Ratio
6.12
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2022-06-30 | -222.91x |
| 2022-03-31 | -12.14x |
| 2021-12-31 | -14.18x |
| 2019-12-31 | -392.17x |
| 2017-03-31 | -690.82x |
| 2016-12-31 | -2202.50x |
